Related Experiment Video
Updated: Mar 19, 2026
02:21
Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
1.8K
Injectable therapy for Peyronie's disease
Weiliang Chong1, Ronny Ban Wei Tan1
1Department of Urology, Tan Tock Seng Hospital, Singapore.
Translational Andrology and Urology
|June 15, 2016
Summary
Peyronie's disease treatments remain inconsistent. Intralesional agents, including the FDA-approved Clostridium histolyticum collagenase (Xiaflex), show promise, but further research into the disease's pathophysiology is needed.
Area of Science:
- Urology
- Andrology
- Regenerative Medicine
Background:
- Peyronie's disease is a challenging condition with significant psychological impact.
- Current therapeutic outcomes for Peyronie's disease are often inconsistent.
- Understanding the underlying pathophysiology is crucial for effective treatment development.
Purpose of the Study:
- To review the evolution and efficacy of intralesional agents for Peyronie's disease.
- To highlight the current landscape of non-surgical treatment options.
Main Methods:
- Review of existing literature on intralesional therapies for Peyronie's disease.
- Analysis of the efficacy of various intralesional agents, including FDA-approved and off-label options.
Main Results:
- Clostridium histolyticum collagenase (Xiaflex) is the only FDA-approved agent with consistent results.
- Other intralesional agents like calcium channel blockers and interferons (IFN) are used off-label.
- The variety of agents trialled indicates incomplete knowledge of the disease's pathophysiology.
Conclusions:
- Intralesional therapies represent a key area of focus for Peyronie's disease management.
- Xiaflex offers a consistent treatment option, while other agents require further investigation.
- Advancing our understanding of Peyronie's disease pathophysiology is essential for future therapeutic innovations.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
591
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
591
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
693
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
693
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
91
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
91
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
537
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
537
01:27Peripheral Artery Disease III: Interprofessional Care
515
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
515
01:21Intrauterine Drug Delivery Systems
106
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
106